X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-31 | NRIX | Ring Christine | GC | S - Sale+OE | $19.95 | -5,760 | 32,538 | -15% | -$114,934 | |||||
| D | 2025-01-30 | NRIX | Ring Christine | GC | S - Sale+OE | $19.85 | -3,220 | 32,538 | -9% | -$63,929 | |||||
| D | 2025-01-30 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $19.85 | -3,690 | 55,937 | -6% | -$73,260 | |||||
| D | 2025-01-30 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $19.85 | -2,811 | 39,549 | -7% | -$55,809 | |||||
| D | 2025-01-02 | NRIX | Ring Christine | GC | S - Sale+OE | $19.50 | -5,760 | 28,084 | -17% | -$112,295 | |||||
| D | 2024-12-02 | NRIX | Ring Christine | GC | S - Sale+OE | $21.73 | -5,760 | 28,084 | -17% | -$125,155 | |||||
| D | 2024-11-04 | NRIX | Ring Christine | GC | S - Sale+OE | $25.00 | -3,290 | 28,084 | -10% | -$82,250 | |||||
| D | 2024-11-01 | NRIX | Ring Christine | GC | S - Sale+OE | $24.28 | -5,760 | 28,084 | -17% | -$139,867 | |||||
2024-11-01 | NRIX | Van Houte Hans | CFO | S - Sale | $24.28 | -3,546 | 33,724 | -10% | -$86,083 | ||||||
| D | 2024-10-30 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $24.31 | -2,368 | 37,270 | -6% | -$57,554 | |||||
| D | 2024-10-30 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $24.31 | -3,437 | 50,670 | -6% | -$83,536 | |||||
| D | 2024-10-30 | NRIX | Ring Christine | GC | S - Sale+OE | $24.31 | -4,182 | 28,084 | -13% | -$101,644 | |||||
| D | 2024-10-14 | NRIX | Ring Christine | GC | S - Sale+OE | $25.00 | -3,290 | 24,592 | -12% | -$82,250 | |||||
| D | 2024-10-01 | NRIX | Ring Christine | GC | S - Sale+OE | $22.23 | -5,760 | 24,592 | -19% | -$128,017 | |||||
| D | 2024-09-03 | NRIX | Ring Christine | GC | S - Sale+OE | $24.94 | -9,050 | 24,592 | -27% | -$225,736 | |||||
| D | 2024-08-26 | NRIX | Ring Christine | GC | S - Sale+OE | $25.01 | -9,870 | 24,592 | -29% | -$246,843 | |||||
2024-08-26 | NRIX | Van Houte Hans | CFO | S - Sale | $25.22 | -20,000 | 31,002 | -39% | -$504,370 | ||||||
2024-08-01 | NRIX | Van Houte Hans | CFO | S - Sale | $21.45 | -3,477 | 51,002 | -6% | -$74,576 | ||||||
| D | 2024-08-01 | NRIX | Ring Christine | GC | S - Sale+OE | $21.43 | -5,760 | 24,592 | -19% | -$123,459 | |||||
| D | 2024-07-30 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $20.67 | -3,408 | 45,150 | -7% | -$70,436 | |||||
| D | 2024-07-30 | NRIX | Ring Christine | GC | S - Sale+OE | $20.67 | -2,920 | 24,592 | -11% | -$60,350 | |||||
| D | 2024-07-30 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $20.67 | -2,490 | 54,479 | -4% | -$51,463 | |||||
| D | 2024-07-01 | NRIX | Ring Christine | GC | S - Sale+OE | $20.81 | -5,760 | 19,838 | -23% | -$119,837 | |||||
2024-06-20 | NRIX | Van Houte Hans | CFO | S - Sale | $20.01 | -20,000 | 48,333 | -29% | -$400,216 | ||||||
| D | 2024-06-13 | NRIX | Ring Christine | GC | S - Sale+OE | $17.02 | -1,864 | 19,838 | -9% | -$31,721 | |||||
| D | 2024-06-12 | NRIX | Ring Christine | GC | S - Sale+OE | $17.01 | -1,900 | 19,838 | -9% | -$32,319 | |||||
| D | 2024-06-05 | NRIX | Ring Christine | GC | S - Sale+OE | $17.00 | -400 | 19,838 | -2% | -$6,801 | |||||
| D | 2024-06-03 | NRIX | Ring Christine | GC | S - Sale+OE | $17.01 | -1,596 | 19,838 | -7% | -$27,153 | |||||
2024-05-02 | NRIX | Van Houte Hans | CFO | S - Sale | $12.83 | -3,499 | 68,333 | -5% | -$44,878 | ||||||
| D | 2024-04-30 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $12.04 | -1,387 | 71,832 | -2% | -$16,703 | |||||
| D | 2024-04-30 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $12.04 | -2,007 | 39,601 | -5% | -$24,169 | |||||
| D | 2024-04-30 | NRIX | Ring Christine | GC | S - Sale+OE | $12.04 | -1,513 | 19,838 | -7% | -$18,220 | |||||
2024-02-16 | NRIX | Van Houte Hans | CFO | S - Sale | $10.02 | -6,812 | 68,333 | -9% | -$68,223 | ||||||
| D | 2024-01-30 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $7.99 | -1,671 | 75,145 | -2% | -$13,352 | |||||
| D | 2024-01-30 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $7.99 | -2,334 | 36,402 | -6% | -$18,649 | |||||
| D | 2024-01-30 | NRIX | Ring Christine | GC | S - Sale+OE | $7.99 | -1,760 | 17,427 | -9% | -$14,063 | |||||
2023-12-20 | NRIX | Van Houte Hans | CFO | S - Sale | $10.00 | -3,541 | 71,930 | -5% | -$35,421 | ||||||
2023-12-19 | NRIX | Van Houte Hans | CFO | S - Sale | $10.00 | -10,906 | 75,471 | -13% | -$109,093 | ||||||
| D | 2023-10-31 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $5.20 | -1,080 | 86,377 | -1% | -$5,613 | |||||
| D | 2023-10-31 | NRIX | Ring Christine | GC | S - Sale+OE | $5.20 | -1,232 | 15,263 | -7% | -$6,403 | |||||
| D | 2023-10-31 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $5.20 | -1,633 | 33,529 | -5% | -$8,487 | |||||
| D | 2023-07-31 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $9.65 | -1,245 | 82,571 | -1% | -$12,020 | |||||
| D | 2023-07-31 | NRIX | Ring Christine | GC | S - Sale+OE | $9.65 | -1,420 | 12,544 | -10% | -$13,710 | |||||
| D | 2023-07-31 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $9.65 | -1,884 | 29,955 | -6% | -$18,189 | |||||
| D | 2023-05-01 | NRIX | Wolff Stefani | EVP, COO | S - Sale+OE | $9.88 | -342 | 6,113 | -5% | -$3,378 | |||||
| D | 2023-05-01 | NRIX | Van Houte Hans | CFO | S - Sale+OE | $9.88 | -721 | 78,930 | -1% | -$7,121 | |||||
| D | 2023-05-01 | NRIX | Ring Christine | GC | S - Sale+OE | $9.88 | -682 | 10,040 | -6% | -$6,736 | |||||
| D | 2023-05-01 | NRIX | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $9.88 | -1,136 | 26,632 | -4% | -$11,219 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |